Key Points
- Janux Therapeutics VP Maria Dobek sold 2,038 shares on May 11 at an average price of $14.17, totaling $28,878.46. The sale reduced her ownership by about 5.94%.
- The stock rose 1.4% and opened at $14.61, near its 50-day moving average of $14.41 but still below its 200-day average of $17.11. The shares remain well off the 12-month high of $35.34.
- Analysts remain broadly positive despite ongoing losses: Wedbush kept a Buy rating, and several firms lifted earnings estimates, though Janux still reported a quarterly loss and is expected to remain unprofitable this year.
Janux Therapeutics, Inc. (NASDAQ:JANX - Get Free Report) VP Maria Dobek sold 2,038 shares of the company's stock in a transaction dated Monday, May 11th. The stock was sold at an average price of $14.17, for a total transaction of $28,878.46. Following the transaction, the vice president owned 32,270 shares in the company, valued at approximately $457,265.90. This trade represents a 5.94% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Janux Therapeutics Stock Up 1.4%
Shares of NASDAQ JANX opened at $14.61 on Thursday. The firm's 50-day simple moving average is $14.41 and its 200 day simple moving average is $17.11. The company has a market cap of $890.92 million, a price-to-earnings ratio of -7.94 and a beta of 2.58. Janux Therapeutics, Inc. has a 12-month low of $12.12 and a 12-month high of $35.34.
Janux Therapeutics (NASDAQ:JANX - Get Free Report) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($0.39) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.52) by $0.13. The company had revenue of $3.73 million for the quarter, compared to analyst estimates of $4.36 million. On average, equities analysts expect that Janux Therapeutics, Inc. will post -1.71 earnings per share for the current year.
Janux Therapeutics News Roundup
Here are the key news stories impacting Janux Therapeutics this week:
- Positive Sentiment: Wedbush kept its Buy rating on Janux Therapeutics, reinforcing a constructive view on the stock. Wedbush Keeps Their Buy Rating on Janux Therapeutics Inc (JANX)
- Positive Sentiment: HC Wainwright raised earnings estimates across multiple periods, including 2026, 2027, 2028, and 2029, suggesting improved expectations for the company’s future financial performance.
- Positive Sentiment: The firm’s Q2, Q3, and Q4 2026 EPS forecasts were all revised upward, which may be interpreted as a sign of improving operating trends.
- Neutral Sentiment: Janux Therapeutics’ vice president, Maria Dobek, sold 2,038 shares at an average price of $14.17, a transaction that slightly reduced insider ownership and may be viewed as a mild overhang. SEC Form 4 filing
- Neutral Sentiment: Despite the analyst optimism, Janux remains unprofitable, and the updated forecasts still point to losses in the coming years.
Wall Street Analyst Weigh In
Several analysts have weighed in on the company. Weiss Ratings raised Janux Therapeutics from a "sell (e+)" rating to a "sell (d-)" rating in a report on Wednesday, April 22nd. Wall Street Zen raised Janux Therapeutics from a "sell" rating to a "hold" rating in a report on Sunday, April 5th. Guggenheim dropped their price objective on Janux Therapeutics from $68.00 to $58.00 and set a "buy" rating for the company in a report on Friday, May 8th. Evercore set a $22.00 price objective on Janux Therapeutics in a report on Monday. Finally, Wedbush dropped their price objective on Janux Therapeutics from $45.00 to $36.00 and set an "outperform" rating for the company in a report on Friday, May 8th. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $45.85.
Read Our Latest Report on Janux Therapeutics
Institutional Trading of Janux Therapeutics
Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. BML Capital Management LLC bought a new stake in Janux Therapeutics during the 1st quarter worth about $2,154,000. Allspring Global Investments Holdings LLC bought a new stake in shares of Janux Therapeutics in the 1st quarter valued at about $2,452,000. Bleakley Financial Group LLC bought a new stake in shares of Janux Therapeutics in the 1st quarter valued at about $265,000. Hsbc Holdings PLC bought a new stake in shares of Janux Therapeutics in the 1st quarter valued at about $711,000. Finally, Y Intercept Hong Kong Ltd bought a new stake in shares of Janux Therapeutics in the 1st quarter valued at about $1,946,000. 75.39% of the stock is owned by institutional investors.
About Janux Therapeutics
(
Get Free Report)
Janux Therapeutics is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX.
Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
